Haig Aghajanian

Haig Aghajanian

Company: Capstan Therapeutics

Job title: Co-Founder & VP of Research


Seminar: Targeted mRNA Lipid Nanoparticles Produce CAR-T Cells In Vivo to Treat Heart Disease

  • mRNA targeted-lipid nanoparticles can specifically reprogram T cells in vivo
  • In vivo mRNA delivery to immune cells can produce functional, transient CAR-T cells directed against activated fibroblasts
  • In vivo produced CAR-T cells can reduce fibrosis and restore function in a fibrotic organ

Day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.